Citation Impact
Citing Papers
Structures of MLSBK Antibiotics Bound to Mutated Large Ribosomal Subunits Provide a Structural Explanation for Resistance
2005 StandoutNobel
Discovery and optimization of nonpeptide HIV-1 protease inhibitors
1996
Structure?Activity Relationships for Three Macrolide Antibiotics in Haemophilus influenzae
2004
Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults
2007 Standout
Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults
2000 Standout
Determination of erythromycin A in rat plasma and urine by high‐performance liquid chromatography with chemiluminescence detection using Tris(2,2′‐bipyridine)ruthenium(II)
2006
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
1999 Standout
Pneumococcal macrolide resistance—myth or reality?
1999
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
1996
Evidence for the Existence of a Non-catalytic Modifier Site of Peptide Hydrolysis by the 20 S Proteasome
2000
Clinical Relevance of Bacteriostatic versus Bactericidal Mechanisms of Action in the Treatment of Gram‐Positive Bacterial Infections
2004
Cytochrome P450 complement (CYPome) of the avermectin-producer Streptomyces avermitilis and comparison to that of Streptomyces coelicolor A3(2)
2003 StandoutNobel
A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
1997 Standout
HIV-Protease Inhibitors
1998
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
1997 Standout
Evaluating the potency of HIV‐1 protease drugs to combat resistance
2007
Tuberculosis in Patients with Human Immunodeficiency Virus Infection
1999 Standout
Incidence of Resistance in a Double‐Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and Lamivudine
2004
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study
1999 Standout
Novel nonpeptidic inhibitors of HIV-1 protease obtained via a new multicomponent chemistry strategy
2004
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
1997 StandoutNature
Structure of a G48H mutant of HIV‐1 protease explains how glycine‐48 replacements produce mutants resistant to inhibitor drugs1
1997
Antibiotics for pneumonia therapy
1994
A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection
1995
A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 Protease
1995
Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition
1997
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals
2011
Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study
2009
Decay characteristics of HIV-1-infected compartments during combination therapy
1997 StandoutNature
A Common Mechanism of Cellular Death Induced by Bactericidal Antibiotics
2007 Standout
Mathematical modeling of primary hepatitis C infection: Noncytolytic clearance and early blockage of virion production
2005 StandoutNobel
Antimicrobial Chemotherapy for Legionnaires' Disease: A Review
1995
Validating the vitality strategy for fighting drug resistance
2011 StandoutNobel
An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases
2007 Standout
The Macrolides: Erythromycin, Clarithromycin, and Azithromycin
1999
Fluorine in medicinal chemistry
2007 Standout
Molecular Recognition of Protein−Ligand Complexes: Applications to Drug Design
1997 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Bioorganometallic Chemistry of Ferrocene
2004 Standout
The stereoselective synthesis of novel macrolide antibacterial agents via an intramolecular 1,3-dipolar cycloaddition of azomethine ylide
2004
HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time
1996 StandoutScience
A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong
2003 Standout
A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia
1997
Novel Heterocyclic Analogues of the HIV‐1 Protease Inhibitor, Ritonavir
2004
Inhibition of human immunodeficiency virus type 1 transcription and replication by DNA sequence-selective plant lignans.
1995
Water as an Active Constituent in Cell Biology
2007 Standout
Chemical parameters influencing fine-tuning in the binding of macrolide antibiotics to the ribosomal tunnel
2007 StandoutNobel
Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms
1992
Synthesis and Antibacterial Activity of Ketolides (6-O-Methyl-3-oxoerythromycin Derivatives): A New Class of Antibacterials Highly Potent Against Macrolide-Resistant and -Susceptible Respiratory Pathogens
1998
The macrolides
2002
Transport, metabolism and elimination mechanisms of anti-HIV agents
1999
Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy
2004 Standout
Recent Developments in Isocyanide Based Multicomponent Reactions in Applied Chemistry
2005 Standout
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Positive Effects of Combined Antiretroviral Therapy on CD4 + T Cell Homeostasis and Function in Advanced HIV Disease
1997 StandoutScience
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
1997 Standout
Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450
1996
Plant Products as Antimicrobial Agents
1999 Standout
The Unenlarged Lymph Nodes of HIV-1–infected, Asymptomatic Patients with High CD4 T Cell Counts Are Sites for Virus Replication and CD4 T Cell Proliferation. The Impact of Highly Active Antiretroviral Therapy
1998 StandoutNobel
Transition-Metal-Catalyzed C−S, C−Se, and C−Te Bond Formation via Cross-Coupling and Atom-Economic Addition Reactions
2011 Standout
High Levels of Viral Replication Contrast with Only Transient Changes in CD4+and CD8+Cell Numbers during the Early Phase of Experimental Infection with Simian Immunodeficiency Virus SIVmnd-1 inMandrillus sphinx
2002 StandoutNobel
An Erythromycin Derivative Produced by Targeted Gene Disruption in Saccharopolyspora erythraea
1991 Science
Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system
1992
Protease Inhibitors: Current Status and Future Prospects
2000
Structural basis for cross-resistance to ribosomal PTC antibiotics
2008 StandoutNobel
The Combinatorial Synthesis of Bicyclic Privileged Structures or Privileged Substructures
2003 Standout
Electrogenerated Chemiluminescence and Its Biorelated Applications
2008 Standout
Applications of Palladium-Catalyzed C–N Cross-Coupling Reactions
2016 Standout
Construction of Enantiopure Pyrrolidine Ring System via Asymmetric [3+2]-Cycloaddition of Azomethine Ylides
2006 Standout
Metal–Organic Frameworks in Biomedicine
2011 Standout
ANTIBIOTICS TARGETING RIBOSOMES: Resistance, Selectivity, Synergism, and Cellular Regulation
2005 StandoutNobel
Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma Viremia
1997 StandoutScience
Association of Saquinavir Plasma Concentrations with Side Effects but Not with Antiretroviral Outcome in Patients Infected with Protease Inhibitor-Susceptible Human Immunodeficiency Virus Type 1
2007
Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy
1997 StandoutScience
The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction
2002 StandoutNobel
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy
1998 StandoutScience
On the identity of a neo-lignan from the fruits of Virola sebifera
1998
Chemistry and Biology Of Multicomponent Reactions
2012 Standout
Selective proteasome inhibitors: modulators of antigen presentation?
1999
Antimicrobial Activities and Postantibiotic Effects of Clarithromycin, 14-Hydroxy-Clarithromycin, and Azithromycin in Epithelial Cell Lining Fluid against Clinical Isolates ofHaemophilus influenzaeandStreptococcus pneumoniae
1999
Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class
1998
The Heck Reaction as a Sharpening Stone of Palladium Catalysis
2000 Standout
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
2002 Standout
Viracept (Nelfinavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease
1997
Works of Edith McDonald being referenced
Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography
1997
Synthesis and antitumor activity of structural analogs of the epipodophyllotoxins
1991
In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide
1986
Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides
1988
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
1997
New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance
1989
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.
1995